CRESCENT BIOPHARMA INC (CBIO) Stock Earnings & Estimates
NASDAQ:CBIO - KYG2545C1042 - Common Stock
13.33 USD
+0.1 (+0.76%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.16M -88.58% | 80K -93.10% | 10K -87.50% | -100.00% | 4.59M | -100.00% | |||||
| EBITDA YoY % growth | -63.19M -23.32% | -47.19M 25.32% | -39.122M 17.10% | N/A 16.99% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -63.45M -23.18% | -47.4M 25.30% | -39.275M 17.14% | -33.887M 17.23% | -66.76M -105.36% | -82.519M -23.60% | -128.961M -56.28% | 100.00% | |||
| Operating Margin | -5,469.83% | -59,250.00% | -392,753.00% | N/A | N/A | N/A | -2,809.62% | N/A | N/A | N/A | |
| EPS YoY % growth | -1.23 -10.81% | -0.88 28.46% | -0.58 34.09% | -0.62 -6.84% | -5.20 -738.41% | -5.49 -5.59% | -7.72 -40.71% | N/A | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.66 -1,381.82% | -1.66 -916.25% | -2.67 33.36% | -2.76 43.93% | -1.39 16.16% | -1.40 15.44% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -18.026M -215.07% | -18.632M -250.53% | -20.502M -474.29% | -21.191M -84.03% | -21.624M -19.96% | -22.44M -20.44% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -4.93 -2,981.25% | -1.80 | -3.13 | -174.23% |
| Q1 2025 Q2Q % growth | -4.00 -2,252.94% | -5.10 | 1.10 | 21.57% |
| Q4 2024 Q2Q % growth | -16.57% | -0.16 | % | |
| Q3 2024 Q2Q % growth | 19.86% | -0.11 | % | |
| Q2 2024 Q2Q % growth | -0.16 -23.08% | -0.17 | 0.01 | 6.35% |
| Q1 2024 Q2Q % growth | -0.17 | -0.17 | 0.00 | -1.01% |
| Q4 2023 Q2Q % growth | -0.14 26.32% | -0.16 | 0.02 | 10.00% |
| Q3 2023 Q2Q % growth | -0.14 12.50% | -0.15 | 0.01 | 4.24% |
| Q2 2023 Q2Q % growth | -0.13 48.00% | -0.19 | 0.06 | 30.48% |
| Q1 2023 Q2Q % growth | -0.17 39.29% | -0.17 | 0.00 | 0.00% |
| Q4 2022 Q2Q % growth | -0.19 42.42% | -0.17 | -0.02 | -11.76% |
| Q3 2022 Q2Q % growth | -0.16 52.94% | -0.27 | 0.11 | 40.43% |
| Q2 2022 Q2Q % growth | -0.25 10.71% | -0.29 | 0.04 | 14.00% |
| Q1 2022 Q2Q % growth | -0.28 | -0.31 | 0.03 | 10.49% |
| Q4 2021 Q2Q % growth | -0.33 -3.13% | -0.34 | 0.01 | 4.14% |
| Q3 2021 Q2Q % growth | -0.34 -17.24% | -0.32 | -0.02 | -4.99% |
| Q2 2021 Q2Q % growth | -0.28 12.50% | -0.31 | 0.03 | 10.73% |
| Q1 2021 Q2Q % growth | -0.28 -55.56% | -0.32 | 0.04 | 13.68% |
| Q4 2020 Q2Q % growth | -0.32 5.88% | -0.33 | 0.01 | 2.57% |
| Q3 2020 Q2Q % growth | -0.29 6.45% | -0.33 | 0.04 | 13.32% |
| Q2 2020 Q2Q % growth | -0.32 13.51% | -0.39 | 0.07 | 17.44% |
| Q1 2020 Q2Q % growth | -0.18 45.45% | -0.31 | 0.13 | 41.95% |
| Q4 2019 Q2Q % growth | -0.34 | -0.35 | 0.01 | 3.85% |
| Q3 2019 Q2Q % growth | -0.31 | -0.40 | 0.09 | 22.47% |
| Q2 2019 Q2Q % growth | -0.37 | -0.37 | 0.00 | 0.16% |
| Q1 2019 Q2Q % growth | -0.33 | -0.35 | 0.02 | 6.03% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | -100.00% | % | ||
| Q2 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2022 Q2Q % growth | -100.00% | % | ||
| Q1 2022 Q2Q % growth | -100.00% | % | ||
| Q4 2021 Q2Q % growth | 20K -87.50% | 20K | % | |
| Q3 2021 Q2Q % growth | 90K -91.00% | 90K | % | |
| Q1 2021 Q2Q % growth | 1.06M -88.22% | 1.06M | % | |
| Q4 2020 Q2Q % growth | 160K | 204K | -44K | -21.57% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | N/A | -48.71% | -25366.7% |
| Revenue | N/A | N/A | N/A | N/A |